10:12 AM
 | 
Dec 01, 2017
 |  BioCentury  |  Finance

Blue skies for Codiak

Why EcoR1 joined Codiak’s $76.5M series C round

EcoR1 opted to join Codiak BioSciences Inc.’s series C round based on the track record of the biotech’s team and the broad utility of its exosome therapeutics platform. The deal aims to get the company its first clinical data in cancer.

On Nov. 29, Codiak raised $76.5 million in an untranched series C round. In addition to EcoR1, other new investors included Casdin Capital, Qatar Investment Authority, Sirona Capital and Tavistock Group’s Boxer Capital. Existing investors Alaska Permanent Fund, Alexandria Venture Investments, Arch Venture Partners, Fidelity and Flagship Pioneering also participated.

Read the full 445 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >